Drug intelligence / Profile preview

PDK-1 shRNA

Development stage
Preclinical
Lead developer
University of Illinois
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

PDK-1 shRNA is a short hairpin RNA (shRNA) designed to silence the expression of pyruvate dehydrogenase kinase 1 (PDK-1). In the context of glioblastoma multiforme (GBM), PDK-1 is often upregulated by hypoxia and contributes to the Warburg effect, where cancer cells prioritize glycolysis over oxidative phosphorylation. By knocking down PDK-1, this therapeutic approach aims to reverse the metabolic phenotype of GBM cells, thereby inhibiting tumor growth, invasion, and the expression of associated oncogenic factors like EGFR and HIF-1α. Research conducted at the University of Illinois College of Medicine at Peoria has demonstrated that PDK-1 knockdown, either alone or in combination with EGFR knockdown or human umbilical cord blood stem cells (hUCBSC), can effectively suppress the malignant progression of GBM.

Other names
pyruvate dehydrogenase kinase 1 short hairpin RNA
02

Targets

PDK (Pyruvate dehydrogenase kinase isoform 1)Innate immune double-stranded RNA sensors

Beyond the preview

Go deeper on PDK-1 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDK-1 shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call